•GMAC names 2026-2027 international advisory panel •AMA supports formal classification of myopia as a disease•FDA grants IDE approval to Ciliatech for glaucoma implant study •FDA accepts Nanoscope's optogenetic gene therapy BLA for RP•Deep learning ties retinal features to Alzheimer's risk factors•GMAC names 2026-2027 international advisory panel •AMA supports formal classification of myopia as a disease•FDA grants IDE approval to Ciliatech for glaucoma implant study •FDA accepts Nanoscope's optogenetic gene therapy BLA for RP•Deep learning ties retinal features to Alzheimer's risk factors
HEADLINES
FEATURED
Promising early results pave the way for a higher-dose cohort; FDA meeting signals potential phase 3 trial in 2027.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
